Search Results

Press Releases

Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer

November 6, 2024

·

7 min read

News

Nouscom to Present Updated Positive Data on NOUS-209’s Potential to ‘Intercept’ Cancer in Lynch Syndrome Carriers at SITC 2024

October 4, 2024

·

4 min read

Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines

Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom’s Series C financing round Financing will enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key clinical proof-of-concept endpoints.

March 21, 2024

·

6 min read

Nouscom’s Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential to ‘Intercept’ Cancer in Subjects with Lynch Syndrome

Nouscom today announced that promising interim data from a Phase 1b trial evaluating NOUS-209 in Lynch Syndrome (LS) carriers was published in a Late-breaking Abstract and will be presented in an oral abstract presentation on 4th November 2023 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, USA.

October 31, 2023

·

5 min read

Press Releases

Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice President, Technical and CMC Development

July 17, 2024

·

4 min read

Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round

Nouscom announced the completion of its oversubscribed Series C equity financing raising €67.5 million from a syndicate of renowned international healthcare investors.

November 14, 2023

·

8 min read

Business

Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee

Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that has resulted in the approval of multiple innovative medicines.

May 14, 2024

·

4 min read

Drug Development

Nouscom Presents New Positive Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, in a Late-Breaking Abstract at AACR 2023

Nouscom announced new translational and biomarker data obtained from the ongoing Phase 1b trial evaluating NOUS-PEV in patients with metastatic melanoma.

April 18, 2023

·

3 min read

Drug Development

Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy

Nouscom announced that new translational data obtained from the ongoing Phase 1b trial evaluating NOUS-PEV in patients with metastatic melanoma has been accepted for presentation in a Late-Breaking session at the 2023 American Association for Cancer Research Annual Meeting.

March 15, 2023

·

2 min read

Business

Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director

Nouscom announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.

November 15, 2018

·

2 min read